Wave Life Sciences
WVE | NASDAQ
$2.87
-$0.26 (-8.31%)
At close: Nov 16, 2026, 4:00 PM ET
$2.87
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:31 PM ET
Wave Life Sciences Company Profile
Company profile explainedCompany Profile
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company’s medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-008, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of liver disease; WVE-N531, an exon splicing oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington’s disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore.
Key Executives
| Name | Position |
|---|---|
| Paul Bolno | President, Chief Executive Officer & Director |
| Chandra Vargeese | Chief Technology Officer |
| Kyle Moran | Chief Financial Officer & Principal Accounting Officer |
| Christopher Francis | Senior Vice President of Corporate Development & Head of Emerging Areas |
| Daryn Lewis | Senior Vice President & Head of Human Resources |
| Erik Ingelsson | Chief Scientific Officer |
| Gregory L. Verdine | Founder & Director |
| Hsiu-Chiung Yang | Senior Vice President of Translational Medicine |
| Kate Rausch | Vic President of Corporate Affairs & Investor Relations |
| Katie Sullivan | Senior Director of Corporate Communications |
| Linda Rockett | Senior Vice President & General Counsel |
| Sridhar Vaddeboina | Senior Vice President of Chemistry, Manufacturing & Controls |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 27, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Oct 27, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Oct 27, 2026 | 10-Q | Quarterly Report |
| Oct 27, 2026 | 8-K | Current Report |
| Oct 14, 2026 | ARS | Filing |
| Oct 14, 2026 | DEF 14A | Filing |
| Oct 07, 2026 | 4 | Filing |
| Oct 07, 2026 | 4 | Filing |
| Oct 07, 2026 | 4 | Filing |
| Oct 07, 2026 | 4 | Filing |
Wave Life Sciences
| Country | United States |
| IPO Date | Nov 11, 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 317 |
| CEO | Paul Bolno |
Contact Details
733 Concord Avenue Cambridge,
Massachusetts 02138 United States
Stock Details
| Ticker Symbol | WVE |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001631574 |
| CUSIP Number | 94352A104 |
| ISIN Number | US94352A1043 |
| SIC Code | 2834 |
Recent News
- 3 months ago / 247wallst.comWave Life Sciences: A $1 Billion RNA-Medicine Bargain Ripe for Pharma Takeover
- 3 months ago / seekingalpha.comWave Life Sciences Ltd. (WVE) Presents at Bank of America SMID Cap Virtual Conference Transcript
- 3 months ago / globenewswire.comWave Life Sciences Announces Completion of Redomiciliation to Delaware
- 3 months ago / globenewswire.comWave Life Sciences to Present at Upcoming Investor Conferences
- 4 months ago / seekingalpha.comWave Life Sciences Ltd. (WVE) Q2 2026 Earnings Call Transcript
- 4 months ago / zacks.comWave Life Sciences (WVE) Reports Q2 Loss, Misses Revenue Estimates
- 4 months ago / globenewswire.comWave Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Update
- 4 months ago / globenewswire.comWave Life Sciences Second Quarter 2026 Financial Results Scheduled for July 30, 2026
- 4 months ago / zacks.comWave Life Sciences (WVE) Upgraded to Strong Buy: What Does It Mean for the Stock?
- 4 months ago / globenewswire.comWave Life Sciences Announces Singapore Court Hearing, to be held on July 14, 2026 to Approve Scheme of Arrangement for Redomiciliation
Add to Watchlist
Select watchlists to add or remove WVE